The Collaborative Fund partner answers our burning questions.
Our insiders say Ancestry’s trove of DNA data is a huge moat.
A deal with Google was sweet news for ADT and sour grapes for the competition.
Empty stadiums are creepy, but cardboard fans are creepier -- and virtual fans might be the creepiest.
Tai Lopez, better known as the “here in my garage” guy, has another turnaround project.
You can make jokes about that $9 latte, but plant-based milk is nothing to scoff about.
A handful of industries received half the funds.
The deal to acquire OneWeb puts the government on a collision course with Elon Musk’s Starlink.
Lemonade and Accolade continued a recent run of successful Wall Street debuts.
The government wanted in, but Telegram’s founder said nyet.
The tools are vital, because the mountain of medical research on COVID-19 is growing.
Loïc Gouzer, once dubbed “the daredevil of the art world,” is back.
Video conferencing isn’t going away anytime soon, so some startups are making lemonade out of lemons.
Hey turned heads with its innovative approach to email, but quickly ran into an Apple problem.
The justices said a major federal civil-rights law covers discrimination on the basis of sexual orientation and gender identity.
Here’s why everyone’s got the hotz for Hertz.
The sales may not help mend the airline’s reputation -- British lawmakers called it the company a “national disgrace.”
You’re not losing your mind: Two companies named for the same dead inventor are jockeying for room in the fast lane.
Employees at Adidas, Microsoft, and other big companies are turning up the heat.
When Greg Glassman spoke out, his company’s partners said they’d seen enough.
In a letter, 140+ scientists said the “spread of deliberate misinformation and divisive language” is antithetical to the initiative’s mission.
A recap of what we got right and wrong.
Zoom’s Q1 revenues were up 169% over last year.
Social platforms are central to the booming protest movement. CEOs who lead them are feeling the heat.
Experts say fortuitously timed trades of Moderna and Gilead Sciences could draw scrutiny from regulators.